Global Advanced Research Journal of Medicine and Medical Sciences (GARJMMS) ISSN: 2315-5159
January 2017 Vol. 6(2), pp. 025-027
Copyright © 2017 Global Advanced Research Journals
Full Length Research Paper
The response rate in chronic migraine patients after the first session of Onabotulinumtoxin A injection, a single center experience from Saudi Arabia
Assistant Professor of Neurology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.
Building 10, second floor, department of medicine, King Abdulaziz University Hospital. P.O.Box 80215. Jeddah 21589
E-mail: email@example.com; Phone number: +966541171145
Accepted 30 January, 2017
Chronic migraine needs a unique approach in management that includes oral prophylactic medications and eventually injection of Onabotulinumtoxin A (Onabot A) to improve patient outcome and quality of life. We aimed to find out the incidence of chronic migraine in a single center experience in Saudi Arabia in addition to the response of injection to Onabot A Retrospective analysis of the occurrence of chronic migraine in our patients. The data were collected to evaluate the response rate after the first injection of Onabot A with emphasis on pain relief in 30 days after the injection session. Among 212 migraine patients, 14 were labeled with the diagnosis of chronic migraine that received Onabot A. 12 of them were female with a mean age of 51.4 +/- 15.3 (25-86). 78.6% had excellent response with reduction of more than 50% of their migraine attacks and eventually changing into episodic migraine. We presented an excellent response rate of Onabot A injection in carefully selected chronic migraine patients after the first injection session.
Keywords: Migraine, chronic migraine, Onabotulinumtoxin A